Captor Therapeutics (CTX) investor relations material

Executive summary

• Focused on targeted protein degradation (TPD) for oncology and autoimmune diseases, with five proprietary drug development projects in the pipeline and several advanced candidates in clinical and preclinical stages.

• Continued R&D investments led to a net loss, typical for the biotech sector at this stage, as projects are not yet commercialized.

• Major capital increase through a private placement of series Y shares, raising 65.6 million PLN, with funds received after the reporting period.

• No significant changes in group structure or business model; main activities remain R&D and partnership/licensing.

Financial highlights

• Q1 2026 consolidated revenue from R&D services: 328 thousand PLN, down from 2,606 thousand PLN year-over-year.

• Net loss for Q1 2026: 11,375 thousand PLN, similar to Q1 2025.

• Operating loss: 11,262 thousand PLN in Q1 2026.

• Cash flow from operations: -12,600 thousand PLN; investing: 1,373 thousand PLN; financing: -1,092 thousand PLN.

• Total assets at March 31, 2026: 26,097 thousand PLN; equity: 12,054 thousand PLN.

Outlook and guidance

• R&D spending expected to increase, especially for projects beyond viadrudomide and vratitoclax.

• Anticipated rise in revenue from new project development and potential partnerships.

• Current cash position, including post-period capital raise, expected to fund operations through Q3 2027.

• Key future drivers: partnership negotiations, research progress, and grant funding.